Abstract | BACKGROUND: METHODS: We conducted an open-label, non-inferiority, phase III, randomized, controlled trial. Eligible patients with stage IIB-IVA cervical carcinoma were randomly assigned to receive either nedaplatin or cisplatin for two cycles concurrently with radiotherapy. We reported the therapy-associated harms and survival. The study was registered with chictr.org.cn, number ChiCTR1800020527. RESULTS: CONCLUSION: Our findings showed that nedaplatin-based concurrent chemoradiotherapy expressed remarkably higher severe hematologic harms which were mortal. Though the results were negative, the experiences and lessons we learned from it were important.
|
Authors | Shasha He, Yan Wang, Yulin Lai, Xinping Cao, Yufeng Ren, Yong Chen |
Journal | Frontiers in oncology
(Front Oncol)
Vol. 11
Pg. 798617
( 2021)
ISSN: 2234-943X [Print] Switzerland |
PMID | 35186715
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 He, Wang, Lai, Cao, Ren and Chen. |